{
    "clinical_study": {
        "@rank": "161652", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give CI-1012 to\n      HIV-infected patients who do not have any symptoms of the disease. This study also examines\n      how the body handles CI-1012."
        }, 
        "brief_title": "A Study of CI-1012 in HIV-Infected Patients", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients receive 2 weeks of oral CI-1012 therapy in this open-label study, with 8 patients\n      entered at each dose level studied."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Serologic evidence of infection with HIV-1.\n\n          -  CD4+ cell count >= 200 cells/mm3.\n\n          -  HIV-1 RNA >= 10,000 copies/ml.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions are excluded:\n\n        Viral, fungal, or bacterial infection requiring therapy other than topical medications.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Prophylactic systematic antibacterial, antifungal or antiviral agents.\n\n          -  Antiretroviral therapy. NOTE:\n\n          -  Patient must be willing to remain off antiretroviral therapy for 1 week after\n             completing study medication.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Experimental therapy for >= 4 weeks prior to initiation of study medication.\n\n          -  Antiretroviral treatment for 3 weeks prior to initiation of study medication.\n\n          -  Systemic steroids or anticancer agents for 4 weeks prior to initiation of study\n             medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "32", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002196", 
            "org_study_id": "278A", 
            "secondary_id": "1012-005"
        }, 
        "intervention": {
            "intervention_name": "CI-1012", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Dose-Response Relationship, Drug", 
            "Administration, Oral", 
            "Drug Administration Schedule", 
            "CD4 Lymphocyte Count", 
            "Anti-HIV Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Palm Springs", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92262"
                    }, 
                    "name": "ViRx Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94109"
                    }, 
                    "name": "ViRx Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Maitland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32751"
                    }, 
                    "name": "Central Florida Research Initiative"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20892"
                    }, 
                    "name": "Natl Institutes of Health"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Multiple Oral, Rising-Dose, Tolerance and Pharmacokinetic Trial of CI-1012 in HIV-1-Infected Volunteers.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002196"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Parke-Davis", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 1998"
    }, 
    "geocoordinates": {
        "Central Florida Research Initiative": "28.628 -81.363", 
        "Natl Institutes of Health": "38.985 -77.095", 
        "ViRx Inc": "37.775 -122.419"
    }
}